Collect Product
Product Details
Source
Anti-Cetuximab Antibody (AY28) (Cat. No. CEB-Y28) is a mouse monoclonal antibody produced from a hybridoma generated by fusion of SP2/0 myeloma cells with mouse B lymphocytes.
Antibody Type
Hybridoma Monoclonal
Clone
AY28
Isotype
Mouse IgG1, Kappa
Host Species
Mouse
Immunogen
Cetuximab
Specificity
Recognizes Cetuximab specifically, no cross reactivity with other humanized antibodies.
Application
ApplicationRecommended Use / PerformanceELISA0.2-2 μg/mLPurification
Protein A purified.
Aggregation
Less than 5%, as determined by SEC-MALS.
Concentration
Please refer to the Certificate of Analysis (CoA).
Form
Lyophilized
Formulation
Lyophilized from a 0.22 μm-filtered solution in Tris (pH 7.5) containing 100 mM Glycine, 25 mM Arginine and 150 mM NaCl, with trehalose as protectant.
Please contact us for customized product forms or formulations.
Reconstitution
Please refer to the Certificate of Analysis (CoA) for specific instructions.
Shipping
Lyophilized product is shipped at ambient temperature.
Storage
For long term storage, the product should be stored in a lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 12 months under sterile conditions after reconstitution.
Notices
Product Specific Notices: For research use only.
ACRO Quality Management System
Kunden haben auch angesehen
Data Display
Bioactivity-ELISA
Immobilized Cetuximab (Cat. No. cetuximab) at 1 μg/mL (100 μL/well) can bind Anti-Cetuximab Antibodies (Cat. No. CEB-Y28) with a linear range of 0.2-3 ng/mL (QC tested).
Protocol
Anti-Cetuximab Antibodies bridging ELISA for Anti-Drug Antibody (ADA) assay development. Immobilized cetuximab at 1 µg/mL, add increasing concentrations of Anti-Cetuximab Antibody (AY28) (Cat. No. CEB-Y28, 10% human serum) and then add biotinylated cetuximab at 5 µg/mL. Detection was performed using HRP-conjugated streptavidin with a sensitivity of 2.4 ng/mL.
Protocol
Immobilized cetuximab at 0.2 μg/mL (100 μL/well) can bind pre-mixed Anti-Cetuximab Antibody (AY28) (Cat. No. CEB-Y28) and Biotinylated Human EGFRvIII, His,Avitag (Cat. No. EGR-H82E0) with an inhibition rate of 100%.
Protocol
The specificity of Monoclonal Anti-Cetuximab Antibody, Mouse IgG1 (AY28) (Cat. No. CEB-Y28) was evaluated by ELISA. Cetuximab was immobilized at 0.1 μg/mL (100 μL/well). AY28 specifically recognized Cetuximab, with no detectable binding to the tested human IgG1 controls, EGFR, Adalimumab, or Bevacizumab under the tested conditions (Routinely tested).
Protocol
Bioactivity-SPR
Anti-Cetuximab Antibody (AY28) (mouse IgG1, Cat. No. CEB-Y28) captured on CM5 chip via anti-mouse antibodies surface, can bind Human cetuximab with an affinity constant of 1.51 pM.
Protocol
User Reviews Publish Comment
FAQ
- product
Can lyophilized proteins remain stable during room-temperature shipping or temporary room-temperature exposure?
In general, lyophilized proteins remain stable during room-temperature shipping or temporary exposure to room-temperature conditions.
Many ACROBiosystems recombinant proteins are supplied in lyophilized (freeze-dried) form. The lyophilization process effectively removes moisture from the product, helping reduce degradation-related reactions and improve protein stability during transportation and storage.
To evaluate the stability of lyophilized proteins under normal temperature conditions, ACROBiosystems conducted a stability study on 11 representative lyophilized protein products at 37°C. The study demonstrated that these proteins maintained good quality stability after storage at 37°C for approximately 20 days. Based on these validation results, temporary room-temperature exposure during shipping or handling is generally not expected to have a significant impact on product quality or downstream application performance.
To ensure optimal long-term stability, products should be stored according to the storage conditions specified in the product Certificate of Analysis (COA) upon receipt.
Supporting Document
Contact Us
Drug Candidate Licensing
